A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 304
- Population
- ALL · 50 Years
- Duration
- 2026-05-27 to 2028-01-12
- Intervention
- ABP 938 8 mg; Aflibercept (US) 8 mg
- Comparator
- Aflibercept (US) 8 mg
- Outcomes measured
- Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score — Baseline…; Percentage of Participants With Absence of Intraretinal Fluid (IRF) and Subretinal Fluid (SRF) in the Center Subfield,…; Change from Baseline in BCVA as measured by ETDRS letter score — Baseline to Week 48; Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 24 — Baseline to Week 24; Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 48 — Baseline to Week 48; Change From Baseline in Choroidal Neovascularization (CNV) Area Size as Measured by Fluorescein Angiography (FA) — Base…; Change From Baseline in Central Subfield Thickness (CST) as Measured by SD-OCT — Baseline to Week 48; Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imag…; Number of Participants Who Experienced Ocular Treatment-Emergent Adverse Events (TEAEs) — Baseline up to Week 48; Number of Participants Who Experienced Non-Ocular TEAEs — Baseline up to Week 48; Number of Participants Who Experienced Treatment-Emergent Events of Interest (EOI) — Baseline up to Week 48; Number of Participants Who Experienced Treatment-Emergent Serious Adverse Events (TESAEs) — Baseline up to Week 48; Number of Participants Who Developed Binding Antidrug Antibodies (ADAs) — Baseline up to Week 48; Free serum concentrations of ABP 938 8 mg — Week 16, week 24 and 48 (End of Study); Free serum concentrations of Aflibercept (US) 8 mg — Week 16, week 24, and 48 (End of Study); Pharmacokinetic (PK) parameters of ABP 938 8mg derived from concentration - time profiles following the first dose in a…; Pharmacokinetic parameters of Aflibercept (US) 8 mg derived from concentration - time profiles following the first dose…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.